Ahmet Demirkazık

Ahmet Demirkazık

Ankara University - Ankara / Türkiye
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 190938
Ankara Üniversitesi
person_outline Ahmet Demirkazık's MOST POPULAR ARTICLES
1-) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...The Lancet 394 (10212), 1929-1939, 20199612019
2-) Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...The Lancet Oncology 22 (1), 51-65, 20211982021
3-) Severe vascular toxicity associated with cisplatin‐based chemotherapyF İçli, H Karaoǧuz, D Dinçol, A Demirkazik, N Günel, R Karaoǧuz, A ÜnerCancer 72 (2), 587-593, 19931651993
4-) Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancerF Icli, H Akbulut, G Utkan, B Yalcin, D Dincol, A Isikdogan, A Demirkazik, ...Journal of surgical oncology 95 (6), 507-512, 20071372007
5-) Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non …NH Hanna, R Kaiser, RN Sullivan, OR Aren, MJ Ahn, B Tiangco, ...Journal of Clinical Oncology 31 (15_suppl), 8034-8034, 20131022013